3/12
08:36 am
agen
Agenus Inc. (NASDAQ: AGEN) had its price target lowered by analysts at Robert W. Baird from $6.00 to $3.00. They now have a "neutral" rating on the stock.
Medium
Report
Agenus Inc. (NASDAQ: AGEN) had its price target lowered by analysts at Robert W. Baird from $6.00 to $3.00. They now have a "neutral" rating on the stock.
3/12
08:05 am
agen
Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/11
11:57 am
agen
Agenus (AGEN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Agenus (AGEN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
3/11
07:36 am
agen
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program [Yahoo! Finance]
Medium
Report
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program [Yahoo! Finance]
3/11
07:30 am
agen
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
Medium
Report
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
2/26
04:48 pm
agen
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
High
Report
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
2/25
02:30 pm
agen
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Low
Report
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
2/25
08:26 am
agen
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
High
Report
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2/24
08:33 am
agen
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
Medium
Report
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
2/12
01:42 pm
agen
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting [Yahoo! Finance]
Medium
Report
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting [Yahoo! Finance]
2/12
01:00 pm
agen
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Medium
Report
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
2/5
06:17 pm
agen
Are Medical Stocks Lagging Agenus (AGEN) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Agenus (AGEN) This Year? [Yahoo! Finance]
1/30
07:12 am
agen
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development [Yahoo! Finance]
Low
Report
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development [Yahoo! Finance]
1/29
12:37 pm
agen
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
Low
Report
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
1/22
02:48 pm
agen
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Medium
Report
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
1/22
08:14 am
agen
Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
12/18
07:36 am
agen
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers [Yahoo! Finance]
Medium
Report
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers [Yahoo! Finance]
12/18
07:30 am
agen
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
High
Report
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
12/16
10:47 am
agen
Vaccine Adjuvants Market to Hit USD 0.96 Billion by 2029 with 6.5% CAGR | MarketsandMarkets™ [Yahoo! Finance]
Medium
Report
Vaccine Adjuvants Market to Hit USD 0.96 Billion by 2029 with 6.5% CAGR | MarketsandMarkets™ [Yahoo! Finance]